Free Trial
NASDAQ:FHTX

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Foghorn Therapeutics logo
$5.01 -0.40 (-7.39%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$5.01 0.00 (0.00%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Key Stats

Today's Range
$4.97
$5.44
50-Day Range
$4.58
$6.50
52-Week Range
$2.94
$10.25
Volume
94,366 shs
Average Volume
96,706 shs
Market Capitalization
$283.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67
Consensus Rating
Buy

Company Overview

Foghorn Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

FHTX MarketRank™: 

Foghorn Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 412th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Foghorn Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Foghorn Therapeutics has received no research coverage in the past 90 days.

  • Read more about Foghorn Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Foghorn Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Foghorn Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Foghorn Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.14% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Foghorn Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Foghorn Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.14% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • News Sentiment

    Foghorn Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Foghorn Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for FHTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.58% of the stock of Foghorn Therapeutics is held by insiders.

  • Percentage Held by Institutions

    61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Foghorn Therapeutics' insider trading history.
Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FHTX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Foghorn Therapeutics Inc (FHTX) - Investing.com
See More Headlines

FHTX Stock Analysis - Frequently Asked Questions

Foghorn Therapeutics' stock was trading at $4.72 at the start of the year. Since then, FHTX shares have increased by 6.1% and is now trading at $5.01.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The business had revenue of $7.56 million for the quarter, compared to analysts' expectations of $7.62 million.

Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of Foghorn Therapeutics include Raymond James Financial Inc. (4.19%), Geode Capital Management LLC (1.43%), Ameriprise Financial Inc. (0.20%) and Panagora Asset Management Inc. (0.12%). Insiders that own company stock include Samuel Agresta and Carlos Costa.
View institutional ownership trends
.

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/05/2025
Today
8/28/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FHTX
CIK
1822462
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$9.00
Potential Upside/Downside
+112.9%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.62 million
Net Margins
-311.90%
Pretax Margin
-311.90%
Return on Equity
N/A
Return on Assets
-28.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.62
Quick Ratio
2.62

Sales & Book Value

Annual Sales
$22.60 million
Price / Sales
12.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-3.68

Miscellaneous

Outstanding Shares
56,530,000
Free Float
52,245,000
Market Cap
$283.22 million
Optionable
Optionable
Beta
3.05

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:FHTX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners